Finding Uninjured Consumers In Drug Antitrust Class Actions

By George Korenko and Tram Nguyen (May 16, 2022, 6:26 PM EDT) -- In an amicus brief filed in March opposing an appeal from end payers seeking to certify a class of end purchasers of the cholesterol drug Niaspan in In re: Niaspan Antitrust Litigation, the Washington Legal Foundation stated that:

Plaintiffs offered the District Court no workable way of identifying members of the class of end-payors they seek to represent from more than 20 million transactions. That is the end of this case.[1]

However, whether class members could be identified was not the only issue in the Niaspan case. The presence of uninjured groups of purported class members was also an issue cited...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!